Skip to main content
ACG 2025 Annual Meeting Main banner

Oral Paper Presentation

Annual Scientific Meeting
Paper/Abstract Presentations

Plenary Session 4B: IBD

Wednesday, October 29, 2025
8:30 AM - 10:15 AM PDT
Location: North Ballroom 120BC

Presentations:

  • 8:30 AM - 8:40 AM PDT
    Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial

    Presenting Author: Vipul Jairath, MBChB, DPhil, MRCP – Department of Medicine and Department of Epidemiology and Biostatistics, Western University

  • 8:40 AM - 8:50 AM PDT
    Duvakitug, an anti-TL1a mAb, Demonstrates Efficacy and Favorable Safety as an Induction Treatment in Adults With Moderately to Severely Active Crohn’s Disease: Results From the RELIEVE UCCD Phase 2b Basket Trial

    Presenting Author: Vipul Jairath, MBChB, DPhil, MRCP – Department of Medicine and Department of Epidemiology and Biostatistics, Western University

  • 8:50 AM - 9:00 AM PDT
    Relationship Between Clinical and Histologic Findings With Tulisokibart Induction at Week 12 and Maintenance Dosing at Week 50 in the Phase 2 Randomized Controlled ARTEMIS-UC Study in Participants With Ulcerative Colitis

    Presenting Author: Brigid S. Boland, MD – Altman Clinical Translational Research Institute, University of California, San Diego

  • 9:00 AM - 9:10 AM PDT
    Guselkumab Maintenance Dose Regimens in Patients With High Disease Activity and Severity: Subgroup Analysis of Participants With Moderately to Severely Active Crohn’s Disease in the GALAXI Phase 3 Studies

    Presenting Author: Anita Afzali, MD, MPH, MHCM, FACG – University of Cincinnati College of Medicine

  • 9:10 AM - 9:20 AM PDT
    Clinical and Endoscopic Improvements With Risankizumab Treatment in Patients With Moderate-to-Severe Crohn’s Disease Who Previously Failed Ustekinumab

    Presenting Author: Jessica R. Allegretti, MD, MPH, FACG (she/her/hers) – Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School

  • 9:20 AM - 9:30 AM PDT
    Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Results From GALAXI 1, 2, & 3 Long-Term Extension

    Presenting Author: Anita Afzali, MD, MPH, MHCM, FACG – University of Cincinnati College of Medicine

  • 9:30 AM - 9:40 AM PDT
    Real-World Comparative Effectiveness of Vedolizumab versus Upadacitinib and Risankizumab for Crohn’s Disease Through 52 Weeks

    Presenting Author: Rahul S. Dalal, MD, MPH (he/him/his) – Brigham and Women's Hospital, Harvard Medical School

  • 9:40 AM - 9:50 AM PDT
    Real World Outcomes of Upadacitinib Compared to Risankizumab as Second-Line Therapy in Patients With Crohn’s Disease Exposed to Tumor Necrosis Factor-Alpha Inhibitors

    Presenting Author: Mira Sridharan, MD (she/her/hers) – Boston Medical Center

  • 9:50 AM - 10:00 AM PDT
    Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT 1 & 2) (Late-Breaking Abstract)

    Late Breaking Abstract Presenter: Bruce E. Sands, MD, MS, FACG – Icahn School of Medicine at Mount Sinai

  • 10:00 AM - 10:10 AM PDT
    AVB-114 Demonstrates Clinical Benefit in Persistent Crohn’s Perianal Fistulas: Results From the Multicenter Randomized STOMP2 Trial (Late-Breaking Abstract)

    Late Breaking Abstract Presenter: David A. Schwartz, MD, FACG (he/him/his) – Vanderbilt University Medical Center